Key result
GLP-1 receptor agonists demonstrate significant renoprotective effects, including reductions in major kidney disease events and albuminuria, in patients with type 2 diabetes and chronic kidney disease.
Why the study?
Although GLP-1 receptor agonists reduce cardiovascular risk, whether they improve clinically important renal outcomes remained unclear beyond reducing albuminuria.
Do Glucagon-like peptide 1 receptor agonists (GLP-1RA) improve renal outcomes in patients with diabetes and chronic kidney disease?
Do Glucagon-like peptide 1 receptor agonists (GLP-1RA) improve renal outcomes in patients with diabetes and chronic kidney disease?
This review highlights the emerging evidence, particularly from the FLOW trial, that GLP-1 receptor agonists provide significant renoprotective benefits in patients with diabetes and chronic kidney disease.
Glucagon-like peptide 1 receptor agonists (GLP-1RA) significantly reduce the risk of cardiovascular disease. However, whether GLP-1RA improves clinically important renal outcomes is still unclear. In cardiovascular outcome trials of GLP-1RA, renal outcomes have been evaluated as secondary outcomes; however, their benefits have not been clarified, except for the effect of reducing albuminuria. Recently, the FLOW trial evaluated the renal benefits of GLP-1RA as a primary outcome in patients with diabetes and chronic kidney disease and showed a significant renoprotective effect. In this review, we discuss the renoprotective effects of GLP-1RA, summarize recently published research results, and describe the known mechanism of renal benefit and outlook.
No takes yet. Share an insight, caveat, or question.
Choi et al. (2025) conducted a review in Type 2 diabetes and chronic kidney disease. Glucagon-like peptide 1 receptor agonists (GLP-1RA) was evaluated. GLP-1 receptor agonists demonstrate significant renoprotective effects, including reductions in major kidney disease events and albuminuria, in patients with type 2 diabetes and chronic kidney disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: